RE: Jashar27 Nov 2021 20:40
Okay, but I think everyone knows exploratory pharma is very high risk. With regards to agile, it’s irrelevant how many options are in the mix. If the product works it will go forward. It’s not a case of we only have 3 slots available and once there gone that’s it.
Personally I don’t believe you can manage risk on pre-clinical AIM pharma stocks. You will never know the result of tests and trials until it’s to late to do anything about it.
Put your money on the table, have the minerals and hold, or alternatively get off the pot. It’s really the simple in my humble opinion.